Workboat Indexes

Roche Holding Ltd (OP: RHHVF )

311.56 +4.20 (+1.37%)

Streaming Delayed Price Updated: 1:39 PM EDT, Oct 11, 2024 Add to My Watchlist

Price and Volume

Volume	700
Open	312.00
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	307.36
Today's Range	309.21 - 313.78
52wk Range	233.12 - 340.88
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta Therapeutics Inc.: Why it's a rising gene therapy star

January 23, 2024

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases.

Via MarketBeat

Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M

January 02, 2024

Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.

Via Benzinga

Performance

YTD	+9.11%	+9.11%
1 Month	+1.82%	+1.82%
3 Month	+8.48%	+8.48%
6 Month	+27.44%	+27.44%
1 Year	+9.32%	+9.32%

More News

Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial

December 11, 2023

Via Benzinga

Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation

December 05, 2023

Via Benzinga

Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs

December 04, 2023

Via Benzinga

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks

October 31, 2023

Via Benzinga

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products

October 19, 2023

Via Benzinga

What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?

October 17, 2023

Via Benzinga

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready

October 11, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges

September 27, 2023

Via Benzinga

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year

September 21, 2023

Via Benzinga

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope

September 07, 2023

Via Benzinga

Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer

September 01, 2023

Via Benzinga

Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time

August 30, 2023

Via Benzinga

Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update

August 23, 2023

Via Benzinga

Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study

August 23, 2023

Via Benzinga

Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients

August 21, 2023

Via Benzinga

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations

July 28, 2023

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List

July 26, 2023

Via Benzinga

Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy

July 24, 2023

Via Benzinga

Nvidia Invested $50 million into This AI Drug Discovery Biotech

July 17, 2023

Via MarketBeat

Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal

July 14, 2023

Via Benzinga

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion

July 13, 2023

Via Benzinga

Agilent Technologies Stock: Ready to Rise off the Floor

June 21, 2023

Via MarketBeat

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

June 21, 2023

Via MarketBeat

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.